Patel, MR, et al., A Phase 1 Evaluation of Tebotelimab, a Bispecific PD-1 x LAG-3 DART® Molecule, in Combination with Margetuximab in Patients with Advanced HER2+ Neoplasms, poster presentation at 2020 SITC Annual Meeting